Connecting Innovation to Purpose

12 Designing a Nectin-4 ADC intended to address Padcev® unmet needs M Toxicity: 3rd gen ADC w/stable linker →Reduce free circulating MMAE Compliance: Extend ADC half-life → Reduce dosing frequency Efficacy: Lower DAR + longer half-life → Dose higher than PadcevⓇ

View entire presentation